Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial - PubMed (original) (raw)

Randomized Controlled Trial

Three-Year Outcomes of Bariatric Surgery vs Lifestyle Intervention for Type 2 Diabetes Mellitus Treatment: A Randomized Clinical Trial

Anita P Courcoulas et al. JAMA Surg. 2015 Oct.

Abstract

Importance: Questions remain about the role and durability of bariatric surgery for type 2 diabetes mellitus (T2DM).

Objective: To compare the remission of T2DM following surgical and nonsurgical treatments.

Design, setting, and participants: In this 3-arm randomized clinical trial conducted at the University of Pittsburgh Medical Center from October 1, 2009, to June 26, 2014, in Pittsburgh, Pennsylvania, outcomes were assessed 3 years after treating 61 obese participants aged 25 to 55 years with T2DM. Analysis was conducted with an intent-to-treat population.

Interventions: Participants were randomized to either an intensive lifestyle weight loss intervention for 1 year followed by a low-level lifestyle intervention for 2 years or surgical treatments (Roux-en-Y gastric bypass [RYGB] or laparoscopic adjustable gastric banding [LAGB]) followed by low-level lifestyle intervention in years 2 and 3.

Main outcomes and measures: Primary end points were partial and complete T2DM remission and secondary end points included diabetes medications and weight change.

Results: Body mass index (calculated as weight in kilograms divided by height in meters squared) was less than 35 for 26 participants (43%), 50 (82%) were women, and 13 (21%) were African American. Mean (SD) values were 100.5 (13.7) kg for weight, 47.3 (6.6) years for age, 7.8% (1.9%) for hemoglobin A1c level, and 171.3 (72.5) mg/dL for fasting plasma glucose level. Partial or complete T2DM remission was achieved by 40% (n = 8) of RYGB, 29% (n = 6) of LAGB, and no intensive lifestyle weight loss intervention participants (P = .004). The use of diabetes medications was reduced more in the surgical groups than the lifestyle intervention-alone group, with 65% of RYGB, 33% of LAGB, and none of the intensive lifestyle weight loss intervention participants going from using insulin or oral medication at baseline to no medication at year 3 (P < .001). Mean (SE) reductions in percentage of body weight at 3 years were the greatest after RYGB at 25.0% (2.0%), followed by LAGB at 15.0% (2.0%) and lifestyle treatment at 5.7% (2.4%) (P < .01).

Conclusions and relevance: Among obese participants with T2DM, bariatric surgery with 2 years of an adjunctive low-level lifestyle intervention resulted in more disease remission than did lifestyle intervention alone.

Trial registration: clinicaltrials.gov Identifier: NCT01047735.

PubMed Disclaimer

Figures

Figure 1

Figure 1. Prevalence of any remission (partial or complete) by treatment group and year

aPartial remission of T2DM - no use of antidiabetics, hemoglobin A1c (HbA1c) level of less than 6.5%, and fasting plasma glucose (FPG) level of125 mg/dL or less Complete remission of T2DM - no use of antidiabetics, HbA1c level of less than 5.7%, and FPG level of 100mg/dL or less Missing data at follow-up were assumed to be no remission. RYGB = Roux-en-Y gastric bypass, LAGB = laparoscopic gastric banding, LWLI = Lifestyle weight loss intervention (intensive) The test of the difference between treatment group p-values are calculated for each time point as follows: year 1 p = <0.0001, year 2 p<0.0001, year 3 p = 0.0037.

Figure 2

Figure 2. Hemoglobin A1c (HbA1c) and Fasting Plasma Glucose (FPG) change by treatment group and year

aBars represent standard error

Figure 3

Figure 3. Diabetes medication usage by treatment group

aBaseline n=20; Year 1; n=18; Year 2 n=18; Year 3 n=18 bBaseline n=21; Year 1 n=19; Year 2 n=17; Year 3 n=20 cBaseline n=20; Year 1 n=14; Year 2 n=14; Year 3 n=14* *One participant was missing medication data

Figure 4

Figure 4. Percent weight change from baseline by treatment groupa

aModeled data, Bars represent standard error (SE)

Comment in

Similar articles

Cited by

References

    1. Look ARG, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–54. - PMC - PubMed
    1. Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56e245. - PubMed
    1. Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222(3):339–50. discussion 350–332. - PMC - PubMed
    1. Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010;61:393–411. - PubMed
    1. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238(4):467–84. discussion 484–465. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources